US 12,433,890 B2
Method of treating SCLC and managing neutropenia
Carmen Kahatt, Madrid (ES); José María Fernandez, Madrid (ES); Salvador Fudio, Madrid (ES); Arturo Soto, Madrid (ES); Pilar Lardelli, Madrid (ES); and Cristian Fernandez, Madrid (ES)
Assigned to PHARMA MAR, S.A., Madrid (ES)
Filed by PHARMA MAR, S.A., Madrid (ES)
Filed on Aug. 10, 2023, as Appl. No. 18/448,124.
Application 18/448,124 is a continuation of application No. 17/777,982, previously published as PCT/EP2020/065093, filed on May 29, 2020.
Claims priority of application No. 19383025 (EP), filed on Nov. 21, 2019; application No. 20382409 (EP), filed on May 14, 2020; and application No. PCT/EP2020/063734 (WO), filed on May 15, 2020.
Prior Publication US 2024/0041874 A1, Feb. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4995 (2006.01); A61K 9/00 (2006.01); A61K 31/4738 (2006.01); A61K 31/4745 (2006.01); A61K 31/573 (2006.01); A61K 38/19 (2006.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01); C07D 519/00 (2006.01)
CPC A61K 31/4995 (2013.01) [A61K 9/0019 (2013.01); A61K 31/4738 (2013.01); A61K 31/4745 (2013.01); A61K 31/573 (2013.01); A61K 38/193 (2013.01); A61P 11/00 (2018.01); A61P 35/00 (2018.01); C07D 519/00 (2013.01); C07B 2200/13 (2013.01)] 30 Claims
 
1. A method of treating metastatic small cell lung cancer (SCLC) in a patient with disease progression after platinum based chemotherapy, said method comprising administering, within 35 days of receiving a dose of 3.2 mg/m2 of lurbinectedin by intravenous infusion as a monotherapy, a dose of 2.6 mg/m2 lurbinectedin by intravenous infusion as a monotherapy to the patient having at the time of the administration of the dose of 2.6 mg/m2 of lurbinectedin:
a) metastatic SCLC with disease progression after platinum-based chemotherapy,
b) a platelet count of at least 100,000/mm3, and
c) an absolute neutrophil count of at least 1500 cells/mm3;
wherein the patient previously experienced Grade 4 neutropenia or any grade febrile neutropenia subsequent to receiving the dose of 3.2 mg/m2 of lurbinectedin.